Tyrosine kinase inhibitor sunitinib targets the vasculature of clear cell renal cell carcinoma

A morphometrical study of treatment effect

Lu Chen, Longwen Chen, Jie Huang, Danfeng Xu, Linhui Wang, Ming Zhou

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tyrosine kinase inhibitor sunitinib is thought to exert its anti-tumor effect by modulating angiogenesis in clear cell renal cell carcinoma (ccRCC). The pathological changes after sunitinib treatment have, however, rarely been studied in surgically resected ccRCC specimens. Such studies are important as they allow researchers to examine whether sunitinib targets the intended tissue and the effectiveness of treatment. We analyzed the pathological and immunohistochemical features of 14 surgically resected ccRCCs following sunitinib treatment and 25 untreated ccRCCs. Treated and untreated ccRCCs were similar in tumor size, nuclear grade and pathological stage. The treated tumors, however, showed significantly higher extent of tumor necrosis (32%) and more likely to have pericellular fibrosis (100%) and vasculopathy involving medium/large vessels (78.6%) compared with untreated tumors (23%, 20% and 40%, respectively, p<0.03). The treated tumors showed 47% reduction in microvessel density demonstrated on CD34 immunohistochemistry compared to the untreated tumors (64 vs 33, p=0.003). Architectural disruption, including vascular dilation and fragmentation, were significantly more common in treated tumors. VEGFR-2 expression (VEGFR-2/CD34 ratio) was higher on tumor microvessels in treated tumors than untreated tumors (0.95 vs 0.81, p=0.04). Our study confirms that tumor microvessels are the primary target of sunitinib treatment in ccRCCs. Sunitinib treatment significantly reduces the microvessel density and also produces significant structural disruption that lead to hypoxia, ischemia and necrosis in tumors. The treatment also increases the VEGFR-2 expression on the residual tumor microvessels and may contribute to the occurrence of resistance to sunitinib treatment.

Original languageEnglish (US)
Pages (from-to)3571-3578
Number of pages8
JournalInternational Journal of Clinical and Experimental Pathology
Volume9
Issue number3
StatePublished - Jan 1 2016

Fingerprint

Renal Cell Carcinoma
Protein-Tyrosine Kinases
Neoplasms
Microvessels
Vascular Endothelial Growth Factor Receptor-2
Therapeutics
sunitinib
Necrosis
Residual Neoplasm
Blood Vessels
Dilatation
Fibrosis
Ischemia
Immunohistochemistry
Research Personnel

Keywords

  • Angiogenesis
  • Clear cell renal cell carcinoma
  • Microvessel density
  • Sunitinib
  • Tyrosine kinase inhibitor
  • VEGFR-2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Tyrosine kinase inhibitor sunitinib targets the vasculature of clear cell renal cell carcinoma : A morphometrical study of treatment effect. / Chen, Lu; Chen, Longwen; Huang, Jie; Xu, Danfeng; Wang, Linhui; Zhou, Ming.

In: International Journal of Clinical and Experimental Pathology, Vol. 9, No. 3, 01.01.2016, p. 3571-3578.

Research output: Contribution to journalArticle

@article{a9f72381db2642d4a46e3a132ec85668,
title = "Tyrosine kinase inhibitor sunitinib targets the vasculature of clear cell renal cell carcinoma: A morphometrical study of treatment effect",
abstract = "Tyrosine kinase inhibitor sunitinib is thought to exert its anti-tumor effect by modulating angiogenesis in clear cell renal cell carcinoma (ccRCC). The pathological changes after sunitinib treatment have, however, rarely been studied in surgically resected ccRCC specimens. Such studies are important as they allow researchers to examine whether sunitinib targets the intended tissue and the effectiveness of treatment. We analyzed the pathological and immunohistochemical features of 14 surgically resected ccRCCs following sunitinib treatment and 25 untreated ccRCCs. Treated and untreated ccRCCs were similar in tumor size, nuclear grade and pathological stage. The treated tumors, however, showed significantly higher extent of tumor necrosis (32{\%}) and more likely to have pericellular fibrosis (100{\%}) and vasculopathy involving medium/large vessels (78.6{\%}) compared with untreated tumors (23{\%}, 20{\%} and 40{\%}, respectively, p<0.03). The treated tumors showed 47{\%} reduction in microvessel density demonstrated on CD34 immunohistochemistry compared to the untreated tumors (64 vs 33, p=0.003). Architectural disruption, including vascular dilation and fragmentation, were significantly more common in treated tumors. VEGFR-2 expression (VEGFR-2/CD34 ratio) was higher on tumor microvessels in treated tumors than untreated tumors (0.95 vs 0.81, p=0.04). Our study confirms that tumor microvessels are the primary target of sunitinib treatment in ccRCCs. Sunitinib treatment significantly reduces the microvessel density and also produces significant structural disruption that lead to hypoxia, ischemia and necrosis in tumors. The treatment also increases the VEGFR-2 expression on the residual tumor microvessels and may contribute to the occurrence of resistance to sunitinib treatment.",
keywords = "Angiogenesis, Clear cell renal cell carcinoma, Microvessel density, Sunitinib, Tyrosine kinase inhibitor, VEGFR-2",
author = "Lu Chen and Longwen Chen and Jie Huang and Danfeng Xu and Linhui Wang and Ming Zhou",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "9",
pages = "3571--3578",
journal = "International Journal of Clinical and Experimental Pathology",
issn = "1936-2625",
publisher = "e-Century Publishing Corporation",
number = "3",

}

TY - JOUR

T1 - Tyrosine kinase inhibitor sunitinib targets the vasculature of clear cell renal cell carcinoma

T2 - A morphometrical study of treatment effect

AU - Chen, Lu

AU - Chen, Longwen

AU - Huang, Jie

AU - Xu, Danfeng

AU - Wang, Linhui

AU - Zhou, Ming

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Tyrosine kinase inhibitor sunitinib is thought to exert its anti-tumor effect by modulating angiogenesis in clear cell renal cell carcinoma (ccRCC). The pathological changes after sunitinib treatment have, however, rarely been studied in surgically resected ccRCC specimens. Such studies are important as they allow researchers to examine whether sunitinib targets the intended tissue and the effectiveness of treatment. We analyzed the pathological and immunohistochemical features of 14 surgically resected ccRCCs following sunitinib treatment and 25 untreated ccRCCs. Treated and untreated ccRCCs were similar in tumor size, nuclear grade and pathological stage. The treated tumors, however, showed significantly higher extent of tumor necrosis (32%) and more likely to have pericellular fibrosis (100%) and vasculopathy involving medium/large vessels (78.6%) compared with untreated tumors (23%, 20% and 40%, respectively, p<0.03). The treated tumors showed 47% reduction in microvessel density demonstrated on CD34 immunohistochemistry compared to the untreated tumors (64 vs 33, p=0.003). Architectural disruption, including vascular dilation and fragmentation, were significantly more common in treated tumors. VEGFR-2 expression (VEGFR-2/CD34 ratio) was higher on tumor microvessels in treated tumors than untreated tumors (0.95 vs 0.81, p=0.04). Our study confirms that tumor microvessels are the primary target of sunitinib treatment in ccRCCs. Sunitinib treatment significantly reduces the microvessel density and also produces significant structural disruption that lead to hypoxia, ischemia and necrosis in tumors. The treatment also increases the VEGFR-2 expression on the residual tumor microvessels and may contribute to the occurrence of resistance to sunitinib treatment.

AB - Tyrosine kinase inhibitor sunitinib is thought to exert its anti-tumor effect by modulating angiogenesis in clear cell renal cell carcinoma (ccRCC). The pathological changes after sunitinib treatment have, however, rarely been studied in surgically resected ccRCC specimens. Such studies are important as they allow researchers to examine whether sunitinib targets the intended tissue and the effectiveness of treatment. We analyzed the pathological and immunohistochemical features of 14 surgically resected ccRCCs following sunitinib treatment and 25 untreated ccRCCs. Treated and untreated ccRCCs were similar in tumor size, nuclear grade and pathological stage. The treated tumors, however, showed significantly higher extent of tumor necrosis (32%) and more likely to have pericellular fibrosis (100%) and vasculopathy involving medium/large vessels (78.6%) compared with untreated tumors (23%, 20% and 40%, respectively, p<0.03). The treated tumors showed 47% reduction in microvessel density demonstrated on CD34 immunohistochemistry compared to the untreated tumors (64 vs 33, p=0.003). Architectural disruption, including vascular dilation and fragmentation, were significantly more common in treated tumors. VEGFR-2 expression (VEGFR-2/CD34 ratio) was higher on tumor microvessels in treated tumors than untreated tumors (0.95 vs 0.81, p=0.04). Our study confirms that tumor microvessels are the primary target of sunitinib treatment in ccRCCs. Sunitinib treatment significantly reduces the microvessel density and also produces significant structural disruption that lead to hypoxia, ischemia and necrosis in tumors. The treatment also increases the VEGFR-2 expression on the residual tumor microvessels and may contribute to the occurrence of resistance to sunitinib treatment.

KW - Angiogenesis

KW - Clear cell renal cell carcinoma

KW - Microvessel density

KW - Sunitinib

KW - Tyrosine kinase inhibitor

KW - VEGFR-2

UR - http://www.scopus.com/inward/record.url?scp=84968928175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968928175&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 3571

EP - 3578

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 3

ER -